Blueprint Medicines (BPMC) – Research Analysts’ Recent Ratings Updates

A number of research firms have changed their ratings and price targets for Blueprint Medicines (NASDAQ: BPMC):

• 11/18/2024 – Blueprint Medicines had its “market outperform” rating reaffirmed by analysts at JMP Securities. They now have a $125.00 price target on the stock.
• 11/15/2024 – Blueprint Medicines had its “buy” rating reaffirmed by analysts at Needham & Company LLC. They now have a $135.00 price target on the stock.
• 11/15/2024 – Blueprint Medicines had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $135.00 price target on the stock.
• 11/14/2024 – Blueprint Medicines is now covered by analysts at JPMorgan Chase & Co.. They set an “overweight” rating and a $126.00 price target on the stock.
• 11/14/2024 – Blueprint Medicines had its “outperform” rating reaffirmed by analysts at Wedbush. They now have a $135.00 price target on the stock.
• 11/8/2024 – Blueprint Medicines was upgraded by analysts at StockNews.com from a “sell” rating to a “hold” rating.
• 10/31/2024 – Blueprint Medicines was downgraded by analysts at StockNews.com from a “hold” rating to a “sell” rating.
• 10/31/2024 – Blueprint Medicines had its price target lowered by analysts at Wells Fargo & Company from $153.00 to $151.00. They now have an “overweight” rating on the stock.
• 10/31/2024 – Blueprint Medicines had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $135.00 price target on the stock.
• 10/30/2024 – Blueprint Medicines had its “buy” rating reaffirmed by analysts at Needham & Company LLC. They now have a $133.00 price target on the stock.
• 10/24/2024 – Blueprint Medicines is now covered by analysts at UBS Group AG. They set a “neutral” rating and a $88.00 price target on the stock.

Blueprint Medicines Stock Performance

Shares of Blueprint Medicines stock traded up $0.47 on Wednesday, reaching $95.10. 813,528 shares of the stock were exchanged, compared to its average volume of 692,660. The company has a current ratio of 3.32, a quick ratio of 3.27 and a debt-to-equity ratio of 1.09. The firm has a market capitalization of $6.04 billion, a PE ratio of -45.07 and a beta of 0.59. Blueprint Medicines Co. has a 1-year low of $67.00 and a 1-year high of $121.90. The business has a fifty day moving average price of $90.67 and a two-hundred day moving average price of $98.28.

Blueprint Medicines (NASDAQ:BPMC) last issued its earnings results on Wednesday, October 30th. The biotechnology company reported ($0.89) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.97) by $0.08. Blueprint Medicines had a negative return on equity of 112.30% and a negative net margin of 29.48%. The business had revenue of $128.20 million during the quarter, compared to the consensus estimate of $127.56 million. During the same period in the prior year, the business posted ($2.20) EPS. The company’s revenue for the quarter was up 126.5% on a year-over-year basis. As a group, research analysts anticipate that Blueprint Medicines Co. will post -3.68 earnings per share for the current fiscal year.

Insider Buying and Selling at Blueprint Medicines

In other news, insider Fouad Namouni sold 3,633 shares of the business’s stock in a transaction that occurred on Thursday, October 3rd. The stock was sold at an average price of $89.32, for a total transaction of $324,499.56. Following the sale, the insider now owns 69,070 shares of the company’s stock, valued at $6,169,332.40. The trade was a 5.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 4.21% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Blueprint Medicines

Hedge funds and other institutional investors have recently bought and sold shares of the company. O Shaughnessy Asset Management LLC increased its position in shares of Blueprint Medicines by 23.9% in the first quarter. O Shaughnessy Asset Management LLC now owns 2,971 shares of the biotechnology company’s stock valued at $282,000 after buying an additional 573 shares in the last quarter. CANADA LIFE ASSURANCE Co increased its holdings in Blueprint Medicines by 3.9% during the 1st quarter. CANADA LIFE ASSURANCE Co now owns 6,834 shares of the biotechnology company’s stock valued at $648,000 after acquiring an additional 256 shares in the last quarter. Lazard Asset Management LLC acquired a new position in Blueprint Medicines during the first quarter worth about $251,000. Kennedy Capital Management LLC purchased a new stake in shares of Blueprint Medicines in the first quarter valued at about $220,000. Finally, Jacobs Levy Equity Management Inc. acquired a new stake in shares of Blueprint Medicines in the first quarter valued at approximately $6,777,000.

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.